2
Clinical Trials associated with Dendritic cells vaccine(Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori)Pembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients With PD-L1 Negative Advanced Mesothelioma Who Have Failed Prior Therapies
Pembrolizumab plus autologous dendritic cell vaccine in patients with PD-L1 negative advanced mesothelioma who have failed prior therapies.This is an exploratory, single-arm, open-label, phase 1b clinical trial.
Patients will receive pembrolizumab 200 mg and autologous dendritic cell vaccine every 3 weeks for the first 6 cycles, followed by pembrolizumab 200 mg every 3 weeks until confirmed progression or for a maximum of 2 years (see Figure 1 Study Schema).
After each vaccine administration patients will receive IL-2 3 MU s.c. for 5 days, from day +2 to day +6.
Autologous Dendritic Cell Therapy for Type 1 Diabetes Suppression: A Safety Study
The proposed studies describe a randomized trial to evaluate the safety of a new diabetes-suppressive cell vaccine, consisting of autologous monocyte-derived dendritic cells treated ex vivo with antisense phosphorothioate-modified oligonucleotides targeting the primary transcripts of the CD40, CD80 and CD86 co-stimulatory molecules (immunoregulatory DC; iDC). The hypothesis to be tested in this study is that iDC are safe and without toxicity in established type 1 diabetic patients.
Fifteen (15) individuals exhibiting fully-established, insulin-dependent type 1 diabetics, without any diabetes-related complications, infectious disease, or other medical anomaly, will be enrolled to establish safety of the approach. 7/15 volunteers will be administered autologous control dendritic cells and 8/15 will be administered iDC. The study is anticipated to be complete by twelve (12) months.
Currently, other than a humanized anti-CD3 antibody with considerable side effects, there is no other means to reverse new-onset type 1 diabetes. These studies will be the first ever to employ autologous dendritic cell transfer to suppress an autoimmune disease and to perhaps reverse it early on in the clinical process.
100 Clinical Results associated with Dendritic cells vaccine(Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori)
100 Translational Medicine associated with Dendritic cells vaccine(Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori)
100 Patents (Medical) associated with Dendritic cells vaccine(Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori)
100 Deals associated with Dendritic cells vaccine(Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori)